PMID- 35282410
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220316
IS  - 2590-1362 (Electronic)
IS  - 2590-1362 (Linking)
VI  - 10
DP  - 2022 Apr
TI  - Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the 
      SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai 
      healthcare workers.
PG  - 100153
LID - 10.1016/j.jvacx.2022.100153 [doi]
LID - 100153
AB  - BACKGROUND: Inactivated vaccine (CoronaVac) and chimpanzee adenovirus-vector 
      vaccine (ChAdOx1) have been widely used in resource-limited settings. However, 
      the information on the reactogenicity and immunogenicity of these two vaccines in 
      the same setting are limited. METHODS: Healthy health care workers (HCWs) aged 
      18 years or older were randomly assigned to receive either two doses of CoronaVac 
      at 4 weeks interval or two doses of ChAdOx1 at 10 weeks interval. Self-reported 
      adverse events (AEs) were collected for 7 days following each vaccination. 
      Immunogenicity was determined by IgG antibodies levels against receptor binding 
      domain (RBD) of the SARS-CoV-2 spike protein (S1 subunit) and the 50% plaque 
      reduction neutralization titers against various strains. RESULTS: Of the 360 
      HCWs, 180 in each vaccine group, the median (interquartile range: IQR) age was 35 
      (29-44) years old and 84.2% were female. Participants who received ChAdOx1 
      reported higher frequency of AEs than those received CoronaVac after both the 
      first dose (84.4% vs. 66.1%, P < 0.001) and second dose (75.6% vs. 60.6%, 
      P = 0.002), with more AEs in those younger than 30 years of age for both 
      vaccines. The seroconversion rates were 75.6% and 100% following the first dose 
      of CoronaVac and ChAdOx1, respectively. All participants were seropositive at 
      2 weeks after the second dose. The anti-SARS-CoV-2 RBD IgG levels induced by 
      CoronaVac was lower than ChAdOX1 with geometric means of 164.4 and 278.5 BAU/mL, 
      respectively (P = 0.0066). Both vaccines induced similar levels of neutralizing 
      antibodies against the Wuhan strain, with the titers of 337.4 and 331.2; however, 
      CoronaVac induced significantly lower GMT against Alpha (23.1 vs. 92.5), Delta 
      (21.2 vs. 69.7), and Beta (10.2 vs. 43.6) variants, respectively. CONCLUSION: 
      CoronaVac induces lower measurable antibodies against circulating variants but 
      with lower frequency of AEs than ChAdOx1. An earlier boosting to prevent 
      breakthrough infections may be needed.
CI  - (c) 2022 Published by Elsevier Ltd.
FAU - Angkasekwinai, Nasikarn
AU  - Angkasekwinai N
AD  - Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 
      Thailand.
FAU - Sewatanon, Jaturong
AU  - Sewatanon J
AD  - Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Thailand.
FAU - Niyomnaitham, Suvimol
AU  - Niyomnaitham S
AD  - Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Thailand.
AD  - Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj 
      Hospital, Mahidol University, Thailand.
FAU - Phumiamorn, Supaporn
AU  - Phumiamorn S
AD  - Department of Medical Sciences, Ministry of Public Health, Thailand.
FAU - Sukapirom, Kasama
AU  - Sukapirom K
AD  - Biomedical Research Incubator Unit, Department of Research, Faculty of Medicine 
      Siriraj Hospital, Mahidol University, Thailand.
AD  - Siriraj Center of Research Excellence in Microparticle and Exosome in Disease, 
      Thailand.
FAU - Sapsutthipas, Sompong
AU  - Sapsutthipas S
AD  - Department of Medical Sciences, Ministry of Public Health, Thailand.
FAU - Sirijatuphat, Rujipas
AU  - Sirijatuphat R
AD  - Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 
      Thailand.
FAU - Wittawatmongkol, Orasri
AU  - Wittawatmongkol O
AD  - Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Thailand.
FAU - Senawong, Sansnee
AU  - Senawong S
AD  - Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Thailand.
FAU - Mahasirimongkol, Surakameth
AU  - Mahasirimongkol S
AD  - Department of Medical Sciences, Ministry of Public Health, Thailand.
FAU - Trisiriwanich, Sakalin
AU  - Trisiriwanich S
AD  - Department of Medical Sciences, Ministry of Public Health, Thailand.
FAU - Chokephaibulkit, Kulkanya
AU  - Chokephaibulkit K
AD  - Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj 
      Hospital, Mahidol University, Thailand.
AD  - Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20220305
PL  - England
TA  - Vaccine X
JT  - Vaccine: X
JID - 101748769
PMC - PMC8896862
OTO - NOTNLM
OT  - ChAdOx1
OT  - CoronVac
OT  - Heath care workers
OT  - Immunogenicity
OT  - Thailand
OT  - Variant of concern
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2022/03/15 06:00
MHDA- 2022/03/15 06:01
PMCR- 2022/03/05
CRDT- 2022/03/14 05:34
PHST- 2021/11/06 00:00 [received]
PHST- 2022/01/26 00:00 [revised]
PHST- 2022/03/01 00:00 [accepted]
PHST- 2022/03/14 05:34 [entrez]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/03/15 06:01 [medline]
PHST- 2022/03/05 00:00 [pmc-release]
AID - S2590-1362(22)00013-4 [pii]
AID - 100153 [pii]
AID - 10.1016/j.jvacx.2022.100153 [doi]
PST - epublish
SO  - Vaccine X. 2022 Mar 5;10:100153. doi: 10.1016/j.jvacx.2022.100153. eCollection 
      2022 Apr.